[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

June 1, 2019

Study Completion Date

June 1, 2019

Conditions
Metastatic Cancer LungMetastatic Ovarian Cancer
Interventions
DRUG

[18F]-AzaFol

\[18F\]-AzaFol is a radiotracer produced at ETH Hönggerberg in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 6 mL of formulated product, the maximal applicable dose being 600 MBq.

DRUG

folarell

"For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to \[18F\]-AzaFol. Due to this low dose of a single injection of folic acid it is unlikely that adverse events would occur.~Folarell® is a folic acid preparation for intravenous or intramuscular injection"

Trial Locations (1)

1011

Lausanne University Hospitals, Lausanne

All Listed Sponsors
collaborator

University Hospital, Zürich

OTHER

collaborator

Cantonal Hospital of St. Gallen

OTHER

lead

University of Lausanne Hospitals

OTHER

NCT03242993 - [18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging | Biotech Hunter | Biotech Hunter